---
title: "The Science Behind GLPMate"
url: https://glpmate.me/science
language: en
description: "How GLPMate estimates medication levels: a pharmacokinetic model with FDA parameters, driven by your dose log. What GLPMate is — and isn't."
---
Science · shown, not asserted

# A health tool you can interrogate.

GLPMate's signature feature is a model, and models deserve scrutiny. Here is exactly how the level curve works, where its numbers come from, and where its authority ends.

## The model

The estimated level curve is a **one-compartment pharmacokinetic model with first-order absorption** — the standard textbook model for subcutaneous depot medications. Every dose you log contributes a term:

C(t) = Σdoses D · f · ( e−ke·Δt − e−ka·Δt )

- **ke** — elimination rate, derived from the medication's published half-life (ln 2 / t½)
- **ka** — absorption rate, fitted so the model's peak matches the label's time-to-peak
- **D, Δt** — your actual dose sizes and times, from your log — not an idealized calendar

Curves are normalized and presented as **percent of your steady-state peak**, because the honest signal is the _shape_ — peaks, troughs, accumulation — not a pseudo-precise ng/mL figure that varies from person to person.

## Parameters, by medication

Active substance | Half-life | Time to peak | Source

Semaglutide (inj.) | ≈ 168 h | 1–3 days | FDA PI, Ozempic/Wegovy

Tirzepatide | ≈ 120 h | 8–72 h | FDA PI, Mounjaro/Zepbound

Dulaglutide | ≈ 112 h | 24–72 h | FDA PI, Trulicity

Liraglutide | ≈ 13 h | 8–12 h | FDA PI, Saxenda/Victoza

Oral semaglutide | ≈ 168 h | ≈ 1 h | FDA PI, Rybelsus

## What the curve is good for

Estimated medication level

90 % of steady state

The shape is the story: peaks, troughs, accumulation

Free

__Recorded __Projected __Steady state Modeled on FDA clinical-pharmacology data

- Explaining why shot day feels different from day six (peak vs trough)
- Showing accumulation — why weeks 1–4 keep changing at the same dose
- Visualizing what a missed or late dose does to your week
- Making cadence conversations (weekly vs 10-day) concrete

## What GLPMate is not

**Not a measurement**

The curve is a population-parameter estimate, not your blood level. Individual absorption and clearance vary.

**Not a medical device**

GLPMate is a tracking and education tool. It performs no diagnosis, no treatment, no dosing calculations for clinical use.

**Not a dosing advisor**

The app and its assistant never suggest changing your dose or schedule. That authority belongs to your prescriber — structurally, not just legally.

**Not a data business**

Your health data funds nothing. No selling, no ad targeting; revenue is the subscription, full stop.

## Primary sources we build on

1. FDA Prescribing Information: Ozempic, Wegovy, Rybelsus (semaglutide); Mounjaro, Zepbound (tirzepatide); Trulicity (dulaglutide); Saxenda, Victoza (liraglutide)
2. Wilding et al., _NEJM_ 2021 — STEP 1 (semaglutide 2.4 mg)
3. Jastreboff et al., _NEJM_ 2022 — SURMOUNT-1 (tirzepatide)
4. Rowland & Tozer — _Clinical Pharmacokinetics and Pharmacodynamics_ (model theory)

Found an error in our method or parameters? We mean it: support.eleutheromania@gmail.com — corrections ship fast.

## See your own curve.

The model runs on your real dose log — free.

[ Download on the **App Store** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=science&adj_redirect_android=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_macos=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235&adj_redirect_windows=https%3A%2F%2Fapps.apple.com%2Fapp%2Fid6788548235) [ GET IT ON **Google Play** ](https://glpmate.go.link?adj_t=22klhq12&adj_campaign=science&adj_redirect_ios=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_macos=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate&adj_redirect_windows=https%3A%2F%2Fplay.google.com%2Fstore%2Fapps%2Fdetails%3Fid%3Dapp.eleutheromania.glpmate)